Human Omental Mature Adipocytes used as Paclitaxel Reservoir for Cell‐Based Therapy in Ovarian Cancer
Advanced Healthcare Materials · 2024-06 · 13 (15)
DOI: 10.1002/adhm.202304206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 04.03.2024. Verfasst von Pacome K Andele und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Venice, 30172, Italy. Hauptthemen laut MEDLINE: Paclitaxel, Ovarian Neoplasms, Adipocytes, Omentum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Ministry of Health, Ricerca Corrente.
Abstract (Originalsprache)
Primary human omental adipocytes and ovarian cancer(OC) cells establish a bidirectional communication in which tumor driven lipolysis is induced in adipocytes and the resulting fatty acids are delivered to cancer cells within the tumor microenvironment. Despite meaningful improvement in the treatment of OC, its efficacy is still limited by hydrophobicity and untargeted effects related to chemotherapeutics. Herein, omental adipocytes are firstly used as a reservoir for paclitaxel, named Living Paclitaxel Bullets (LPB) and secondly benefit from the established dialogue between adipocytes and cancer cells to engineer a drug delivery process that target specifically cancer cells. These results show that mature omental adipocytes can successfully uptake paclitaxel and deliver it to OC cells in a transwell coculture based in vitro model. In addition, the efficacy of this proof‐of‐concept has been demonstrated in vivo and induces a significant inhibition of tumor growth on a xenograft tumor model. The use of mature adipocytes can be suitable for clinical prospection in a cell‐based therapy system, due to their mature and differentiated state, to avoid risks related to uncontrolled cell de novo proliferation capacity after the delivery of the antineoplastic drug as observed with other cell types when employed as drug carriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, Venice, 30172, Italy.
- Department of Pathology, IRCCS CRO Aviano National Cancer Institute, Aviano, 33081, Italy.
- Immunopathology and Cancer Biomarkers unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081, Italy.
- Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia.
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, 34127, Italy.
ORCID-Profile: Pacome K Andele, Flavio Rizzolio
Förderung
- Ministry of Health, Ricerca Corrente
Zitieren
APA
Andele, P. K., Palazzolo, S., Corona, G., Caligiuri, I., Kamensek, U., Cemazar, M., Canzonieri, V., & Rizzolio, F. (2024). Human Omental Mature Adipocytes used as Paclitaxel Reservoir for Cell‐Based Therapy in Ovarian Cancer. Advanced Healthcare Materials, 13(15). https://doi.org/10.1002/adhm.202304206
Vancouver
Andele PK, Palazzolo S, Corona G, Caligiuri I, Kamensek U, Cemazar M, et al. Human Omental Mature Adipocytes used as Paclitaxel Reservoir for Cell‐Based Therapy in Ovarian Cancer. Advanced Healthcare Materials. 2024;13(15). doi:10.1002/adhm.202304206
BibTeX
@article{Andele2024,
author = {Andele, Pacome K and Palazzolo, Stefano and Corona, Giuseppe and Caligiuri, Isabella and Kamensek, Urska and Cemazar, Maja and Canzonieri, Vincenzo and Rizzolio, Flavio},
title = {Human Omental Mature Adipocytes used as Paclitaxel Reservoir for Cell‐Based Therapy in Ovarian Cancer},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {15},
doi = {10.1002/adhm.202304206}
}
EUVIMED